Juvenile Dermatomyositis (JDM) is a rare autoimmune disease characterized by skin and muscle inflammation. The loss of nail fold capillary end row loops (ERL) is evidence of small vessel involvement in JDM. This study aimed to examine the specific association of ERL over the disease course with evidence of JDM disease damage.
Methods
We analyzed data from 68 initially treatment-naïve JDM children who had been observed for at least five years with multiple ERL density assessments. The JDM disease course were categorized into monocyclic short, monocyclic long, polycyclic, and chronic. The ERL capillary count was cumulatively evaluated using the area under the curve (AUC) method.
Results
The mean ERL density for the treatment-naive JDM was significantly lower than that of their healthy age-matched controls (4.8 ± 1.6 /mm vs. 7.9 ± 0.9 /mm; p < 0.0001). The ERL AUC was significantly lower in children with a chronic disease course compared to those with a monocyclic short (p = 0.001) or monocyclic long disease course (p = 0.013). JDM patients with lipodystrophy had lower ERL AUC than those without lipodystrophy (p = 0.04). There was no association between ERL AUC and calcifications or fractures.
Conclusion
Persistently decreased ERL capillary density, reflected by low ERL AUC, is associated with a chronic disease course and lipodystrophy in JDM. Despite medical therapy, the mean ERL count remained below normal even after five years, particularly in polycyclic and chronic cases. It is not clear that restoring normal capillary density is currently feasible in children with JDM.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Juvenile Dermatomyositis (JDM) is a systemic pediatric autoimmune disease characterized by skin and muscle inflammation [1]. Although it is the most common pediatric inflammatory myopathy, with an incidence rate of approximately 3.2 cases per million children in the United States, JDM remains a rare disease [2]. Its etiology is not entirely understood, but it is believed to involve a combination of specific genetic predisposition and environmental factors, such as viral infections and exposure to ultraviolet rays [3, 4].
One of the key features of JDM is the loss of nailfold capillary end row loops (ERL), which can be evaluated at the bedside using capillaroscopy [5‐7]. The loss of capillary ERL indicates small vessel vascular injury, which is further supported by elevated levels of von Willebrand factor antigen (vWF antigen) in the treatment-naïve JDM patients [8]. The reduction in ERL is linked to lower bioavailability of oral prednisone compared to IV methylprednisolone making the oral route of medical therapy less effective [9]. Inadequate treatment of JDM can lead to a higher risk of complications such as calcinosis, deposition of insoluble calcium salts in the skin and subcutaneous tissue, and lipodystrophy [10, 11]. Therefore, defining the association between ERL density and disease progression is important for patient care.
Anzeige
This study aims to examine the association between ERL density over time (5 years) using the area under the curve (AUC) method to define the range of various diseases courses (monocyclic short, monocyclic long, polycyclic, and chronic) in addition to indicators of disease damage (lipodystrophy and calcification).
Methods
Subjects
This retrospective chart review study (IRB# 2012–14,858) was conducted at Ann & Robert H. Lurie Children’s Hospital of Chicago. We included all subjects with the JDM diagnosis based on Bohan and Peter criteria [12, 13] who had at least five years of follow-up data and had at least four ERL assessments at a prespecified time point (0,6,12,24,36,48, and 60 months from initiation of medical therapy). Patients who received medical therapy before the initial ERL assessments, those lacking a five-year follow-up, or those with overlap syndrome were excluded from the analysis. The JDM disease activity was evaluated using standardized scoring systems—the Disease Activity Score (DAS) [14] and Childhood Myositis Assessment Scale (CMAS) [15]. The demographic data of the JDM children are presented in Table 1.
Table 1
Demographic and disease characteristics of the JDM cohort
Frequency (n)
Percentage
Sample size
68
Sex
Female
57
16.2%
Male
11
83.8%
Race/Ethnicity
White
51
75.0%
Hispanic
13
19.1%
African American
2
2.9%
Others
2
2.9%
Myositis specific antibodies
P155/140
28
41.2%
MJ
2
2.9%
Mi2
5
7.4%
MDA5
2
2.9%
Others or multiple MSAs
5
7.4%
Negative
21
30.8%
Not done
5
7.4%
Treatment
Oral steroid
68
100%
Intravenous steroid
64
94.1%
Methotrexate
63
92.6%
Intravenous immunoglobulin
8
11.8%
Hydroxychloroquine
41
60.3%
Cyclosporine
12
17.6%
Mycophenolate
26
38.2%
Disease course
Monocyclic short
12
17.6%
Monocyclic long
29
42.6%
Polycyclic
14
20.6%
Chronic
13
19.1%
The study included 77 healthy children as a control group after providing appropriate written consent (IRB# 2001–11,715). These healthy controls did not have any autoimmune disease or active infection at time of their enrollment. In appreciation for their participation in nailfold capillaroscopy, they received a $25 gift card. Demographic details of healthy controls are available in the supplementary materials (Supplemental Table 1).
Anzeige
Disease course
Children with JDM were categorized into four distinct disease courses according to their treatment response: (A) monocyclic short: if the child completed therapy within the first 36 months without a subsequent disease flare; (B) monocyclic long: if the child completed therapy after 36 months without a subsequent disease flare; (C) polycyclic: if the child had completed treatment but had a subsequent relapse of disease requiring re-initiation of medication; (D) chronic: no clinical resolution within 60 months.
Nailfold capillary ERL studies
Standardized images of the nailfold area were obtained using a Nikon Coolpix p6000 digital camera equipped with a Dermlite2 ProHR (18x). The analysis of the nailfold images was performed by a single experienced observer (GM) using Photoshop. The number of ERL per 3 mm section on each of the eight fingers (excluding thumbs) was counted and subsequently divided by three. Each patient’s mean ERL/mm was calculated by averaging the ERL/mm of the eight fingers [5, 16].
ERL area under the curve calculation
GraphPad Prism was used to calculate the AUC to measure the ERL cumulatively across the study duration. First, the curve was created by plotting the ERL data over time. Then, Prism divides AUC into multiple small trapezoid areas, which are measured individually, using the trapezoid rule [area = ½ (base a + base b) x height], and added up to get the total AUC (Fig. 1).
×
Statistical analysis
The Person’s correlation coefficient was utilized to assess the relationship between ERL at diagnosis and ERL AUC. The student t-test was used to compare the mean ERL AUC of subjects with and without signs of disease damage. Statistical analyses were conducted using IBM SPSS Statistics® and GraphPad Prism® version 9.4.1 was utilized to generate the figures.
Results
The study included 68 treatment-naive JDM children, the majority of whom were female (84%). The racial and ethnic distribution was as follows: 75% Caucasian, 19% Hispanic, 3% African American and 3% Others. Their MSAs (Myositis-specific antibodies) were as follows: 41% P155/140+, 3% MJ+, 7.5% Mi-2+, 3% MDA-5+, 7.5% multiple MSAs, and 31% MSA negative (Table 1). The mean age of onset for JDM was 6 ± 3.1 years, and the mean duration of untreated disease was 9.6 ± 10.2 months (Table 2). The initial disease activity scores were 11.0 ± 3.6 for DAS total, 5.9 ± 1.5 for DAS skin, and 5.1 ± 1.5 for DAS muscle, and CMAS score was 37 ± 10.3 (Table 2). The disease course distribution was as follows: 17.6% monocyclic short, 42.6% monocyclic long, 20.6% polycyclic, and 19.1% chronic (Table 1).
Table 2
Baseline (before treatment) disease activity assessment of the JDM cohort
Reference Range
Mean ± SD
Median (range)
Age (years)
6 ± 3.1
5.4 (1.9–16.4)
Duration of untreated disease (months)
9.6 ± 10.2
6.5 (1–73)
Clinical disease activity indicator
DAS-total
0
11 ± 3.6
11.5 (3–19)
DAS-skin
0
5.9 ± 1.5
6 (2–9)
DAS-muscle
0
5.1 ± 1.5
5 (0–10)
CMAS
52
37 ± 10.3
38 (12–52)
ERL (#/mm)
> 7
5 ± 3.1
4.9 (2.3–10.3)
Laboratory disease activity indicators
Neopterin (nmol/L)
< 10
19.4 ± 10.6
18.5 (2.4–49.3)
ESR (mm/hr)
< 20
19 ± 13.4
15 (3–65)
vWF Antigen
156 ± 75
140 (52–374)
Muscle enzymes
CK (IU/L)
26–27
1700 ± 5291
140 (57-35471)
AST (IU/L)
17–96
107 ± 162.5
46 (22–890)
LDH (IU/L)
147–463
455 ± 392.6
342 (166–2259)
Aldolase (U/L)
3.4–8.6
21.6 ± 41.6
9.9 (2.8–237)
Flow cytometry
Total T cells (CD3+)
64 ± 8.3
64 (41–86)
T helper cells (CD3 + CD4+)
44.4 ± 8
45 (26–64)
T cytotoxic cells (CD3 + CD8+)
18.6 ± 4.4
19 (6–31)
B cells (CD19+)
29 ± 8.3
29 (12–52)
NK cells (CD16+/CD56+)
6.3 ± 3.6
5 (1–15)
The mean ERL count for treatment-naive JDM was 4.8 ± 1.6/mm, which is significantly lower than the healthy control, 7.9 ± 0.9/mm (p < 0.0001). Despite the improvement in mean ERL count over time, it still remained below the expected normal level obtained in healthy controls (6.1–9.7/mm), even after five years of medical therapy (Fig. 2). The rate of improvement varied depending on the different disease courses, with the monocyclic short disease course showing more change than the other groups (4.8 ± 1.5/mm at baseline vs. 6.7 ± 1.5/mm at 12 months, p = 0.038 paired T-test).
Anzeige
×
To evaluate the accumulative effects of chronic ERL capillary loss, the ERL AUC was calculated for each patient (Fig. 1). Although there was a positive correlation between the initial ERL count and ERL AUC, the correlation was not strong (r2 = 0.18, p = 0.001). There was a significant difference between the ERL AUC for monocyclic short vs. chronic (389 ± 46.46 vs. 313 ± 46.69, p = 0.001) and monocyclic long vs. chronic (359 ± 44.53 vs. 313 ± 46.69, p = 0.013) (Fig. 3a). Next, the relationship between ERL AUC and indicators of disease damage (lipodystrophy and calcification) was evaluated. JDM patients with lipodystrophy exhibited a lower ERL AUC than those without lipodystrophy (335.7 ± 52.52 vs. 363.0 ± 47.13, p = 0.04) (Fig. 3b). However, the ERL AUC had no significant association with calcifications (Fig. 3c). Lastly, the relationship between ERL AUC and fractures was assessed, revealing no significant correlation (Fig. 3d).
×
Next, we evaluated the effect of medical treatment on ERL AUC. There was a negative correlation between the duration of oral steroid use and ERL AUC (r2 = 0.12, p = 0.004). Patients who required multiple immunosuppressive medications (additional immunosuppression more than steroid, hydroxychloroquine, and methotrexate) tended to have a lower ERL AUC (339.9 ± 46.8 vs. 371.0 ± 51.0, p = 0.01) (Fig. 4).
Anzeige
×
Discussion
This study provides insight into the association between endothelial dysfunction demonstrated by decreased ERL count and disease progression in children with JDM. Consistent with previous studies, we observed a significantly lower mean ERL density in untreated JDM children compared to healthy controls [6, 7]. This finding supports the concept of endothelial involvement in JDM pathophysiology [3]. Furthermore, the reduction in ERL count often correlates with the severity of skin disease and/or muscle weakness [6, 17], suggesting its possible role as a potential physical exam indicator ofr disease activity. Few studies have evaluated the changes in capillary density and disease activity longitudinally over the disease course [17, 18]. We observed variations in the rate of improvement in ERL count in the different JDM disease courses. Monocyclic disease courses show improvement of the ERL capillary count at a faster rate than that of chronic disease. This finding suggests that the rate of improvement in ERL count may be a more critical factor than the initial ERL count in predicting disease course and outcome.
Despite medical therapy, the mean ERL count in JDM patients remained below normal levels even after five years of treatment, particularly in the polyphasic and chronic disease courses. This implies that the restoration of capillary density might be challenging to achieve and may require additional novel therapeutic strategies to target endothelial dysfunction effectively [19].
Additionally, we utilized the AUC method to evaluate the cumulative change in ERL capillary density over the study period. Our results demonstrated a correlation between ERL AUC and a more chronic disease course, as well as the presence of complications such as lipodystrophy. Of note, we found a weakly positive correlation between the initial ERL count and ERL AUC, which suggests that factors other than the initial capillary density, including MSAs, may contribute to the cumulative capillary loss. For example, it has been shown JDM with anti-P155/140 antibody tend to have lower ERL capillary count and are less likely to have a monophasic disease course [5]. However, our study was not powered enough to investigate the impact of the type or the duration of different MSAs on ERL AUC.
Anzeige
Circulating endothelial cells and markers of endothelial injury, such as vWF antigen, and thrombomodulin are elevated in JDM, providing further evidence of endothelial involvement in the disease pathophysiology [8, 19, 20]. B cell activation and expansion as well as the formation of anti-endothelial cell antibodies have been demonstrated in JDM [21‐24], suggesting other potential mechanisms for endothelial cell injury. Soluble adhesion molecule markers, such as ICAM-1, ICAM-3, and VCAM1, and inflammatory cytokine and markers like neopterin have been used as possible biomarkers of vasculopathy in JDM [25‐27]. These findings highlight the complex interplay between immune dysregulation and endothelial dysfunction in JDM, requiring further investigation to elucidate the underlying mechanisms. Furthermore, it is important to recognize the clinical implications of microvascular injury in JDM as it can affect the gastrointestinal system [28]. The reduced nailfold capillary density observed in JDM has been associated with impaired absorption of oral prednisone, potentially leading to suboptimal drug levels and ineffective treatment [9]. Therefore, administering medications by the intravenous or subcutaneous routes might be preferred in patients with persistently low ERL counts.
The study has several limitations. First, the sample size is relatively small, particularly when considering the potential heterogeneity within the JDM population. Second, the diagnosis of lipodystrophy was based on physician assessment, which can introduce some subjectivity. Lastly, the study was conducted at a single center, potentially limiting the generalizability, especially in geographic regions where P155/140 autoantibodies are not the predominant autoantibody.
Conclusions
Persistently decreased ERL capillary density documented by low ERL AUC is associated with both a chronic disease course and lipodystrophy in JDM. Despite medical therapy, the mean ERL count remained below normal, even after five years, particularly in polycyclic and chronic cases. Therefore, restoring normal ERL capillary density might be challenging and require novel therapeutic strategies targeting endothelial dysfunction.
Acknowledgements
The authors acknowledge and appreciate the contributions of the many Pachman Lab members and the Division of Pediatric Rheumatology who enabled the data collection: Dr. Klein-Gitelman cared for the JDM patients over the past 6 years. Drs. Megan Curran, Kaveh Ardalan and Christopher Costin were also involved. Dr. Amer Khojah started the data analysis while he was on the staff of Ann & Robert H. Lurie Children’s Hospital of Chicago, and completed his work while at Umm Al-Qura University.
Declarations
Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Ann & Robert H. Lurie Children’s Hospital of Chicago (IRB# 2012–14,858). Signed informed consent was obtained from all subjects involved in the study.
Consent for publication
Consent for publication was obtained from all study subjects.
Competing interests
No potential conflict of interest is real or perceived by any of the authors.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.
Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.
Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.
Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.
Update Pädiatrie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.